文献速递脊柱关节炎

银屑病关节炎关键性临床试验中的种族、族裔与地域多样性:仍需进一步进展

Race, Ethnicity, and Geographic Diversity in Pivotal Psoriatic Arthritis Clinical Trials: Further Progress Needed.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2025-08-01

该描述性流行病学研究分析了2000至2019年间启动的29项银屑病关节炎关键性试验,涉及16种靶向治疗药物。在有种族数据的27项试验14165名参与者中,92%为白人,7%为亚裔,黑人、美洲印第安人/阿拉斯加原住民或夏威夷原住民/太平洋岛民合计不足1%。族裔和地域代表性同样有限,作者认为需采取定制化多层面策略提高未来试验参与者代表性。

要点

  • 29项关键性试验中93%报告了种族数据,但期刊发表中46%仅报告白人参与者比例。
  • 14165名参与者中92%为白人,7%为亚裔,黑人等群体合计不足1%。
  • 美国试验活动与州人口规模强相关(r=0.78,P<0.0001),全球站点主要集中在北美和欧洲。

核心结论

  • 银屑病关节炎关键性试验的种族和族裔多样性仍然有限,作者认为需采取定制化多层面策略提高未来试验参与者代表性。

研究设计与样本

  • 描述性流行病学研究,通过期刊发表、Drugs@FDA数据库和ClinicalTrials.gov数据,分析美国获批用于银屑病关节炎的生物制剂和靶向合成改善病情抗风湿药关键性试验中种族、族裔和试验站点地域分布的报告与代表性。
  • 共识别29项关键性银屑病关节炎试验,涉及16种靶向治疗药物,试验启动日期介于2000年至2019年。

主要发现

  • 93%的试验报告了种族数据;期刊发表中种族报告率最高(86%),但其中46%仅报告白人参与者比例。
  • 41%的试验可获得族裔数据,主要来自ClinicalTrials.gov,近年报告有所改善。
  • 在有种族数据的27项试验14165名参与者中,92%为白人,7%为亚裔,黑人、美洲印第安人/阿拉斯加原住民或夏威夷原住民/太平洋岛民合计不足1%。
  • 在有族裔数据的12项试验8105名参与者中,11%为西班牙裔或拉丁裔。
  • 26项试验有地点数据;美国境内试验活动最多的是德克萨斯州(24项试验)、佛罗里达州和宾夕法尼亚州(各22项)、加利福尼亚州(20项),与州人口规模强相关(r=0.78,P<0.0001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We assessed race, ethnicity, and geographic diversity in pivotal trials of biologic and targeted synthetic disease-modifying antirheumatic drugs approved for psoriatic arthritis (PsA) in the United States. METHODS: We conducted a descriptive epidemiologic study, examining the reporting and representation of race, ethnicity, and geographic distribution of trial sites in pivotal PsA trials using data from journal publications, the Drugs@FDA database, and ClinicalTrials.gov. RESULTS: We identified 29 pivotal PsA trials for 16 targeted therapies with start dates between 2000 and 2019. Race data were reported in 93% of trials. Race reporting was highest in journal publications (86%); however, among these, 46% reported only the proportion of White participants. Ethnicity data were available for 41% of trials, primarily from ClinicalTrials.gov, with improved reporting in recent years. Among 14,165 participants in 27 trials with race data, 92% were White, 7% were Asian, and fewer than 1% were Black, American Indian/Alaska Native, or Native Hawaiian/Pacific Islander. Among 8,105 participants in 12 trials with ethnicity data, 11% were Hispanic or Latino individuals. Location data were available for 26 trials. In the United States, trial activity was highest in Texas (24 trials), Florida and Pennsylvania (22 each), and California (20), strongly correlating with state population size (r = 0.78, P < 0.0001). Globally, trial sites were identified in 55 countries, primarily in North America and Europe, with fewer sites in Asia, Africa, and Latin America. CONCLUSION: Racial and ethnic diversity in pivotal PsA trials remains limited. Tailored and multifaceted strategies are needed to improve participant representativeness in future trials.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Choufani M, Ermann J, Goel N, et al. Race, Ethnicity, and Geographic Diversity in Pivotal Psoriatic Arthritis Clinical Trials: Further Progress Needed. Arthritis Care Res (Hoboken). 2025. PMID: 40386882. doi:10.1002/acr.25574

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。